Written by David Kerr, Bill Coar, and Kent Koprowicz

In clinical research, particularly within oncology, Data Monitoring Committees (DMCs) play a pivotal role in ensuring the integrity and safety of clinical trials. With the high volume of oncology studies and the extensive use of DMCs in these trials, it is essential to understand the specific nuances and challenges these committees face. Here, I provide an overview of the critical aspects of DMCs in oncology studies.

Role of DMCs in oncology trials

DMCs are tasked with reviewing interim data and making recommendations regarding the continuation, modification, or termination of a trial based on safety and efficacy endpoints. In oncology studies, these endpoints often include progression-free survival (PFS) and overall survival (OS), which can present unique challenges. For example, DMCs frequently encounter scenarios where positive PFS results are observed alongside less mature and potentially negative OS results. Such a discrepancy necessitates careful consideration and interpretation to ensure patient safety and the scientific validity of the study.

DMCs must navigate the complexities of multiple populations and endpoints within a single trial. An oncology study might prioritize analyzing the all-randomized population while also focusing on specific biomarker populations, such as PD-L1<5%, where the novel treatment is suspected to be particularly effective. These complexities necessitate a thorough understanding of the potential pitfalls of over-interpreting subgroup results and the evolving identification of subgroups based on new information from related studies.

Key challenges in oncology trials

• Conducting open-label oncology studies: Conducting open-label studies in oncology presents several challenges, particularly in later-phase randomized trials. Since both the treating physician and patient are aware of the treatment assignment, immediate withdrawal from the study is more likely, especially if patients are randomized to the control arm. This withdrawal can lead to unequal treatment exposure and follow-up, complicating the interpretation of safety and efficacy data. Additionally, the potential bias in investigator-assessed data, where knowledge of treatment arms may influence the results, requires careful oversight by DMCs and the use of Blinded Independent Review Committees (BIRCs) to ensure objective assessments.
• Managing rapid timelines: Oncology studies often require rapid turnaround times for interim analyses. This rapid timeline demands extensive preparation, including conducting numerous test runs with fake randomization to ensure a smooth process. Scheduling placeholder meetings in advance can also help accommodate the uncertain timing of critical events, such as confirming the necessary number of events by the BIRC.
• Data interpretation with high censoring: Another challenge is interpreting data when there is a high rate of censoring due to patients receiving other anti-cancer therapies or withdrawing from the study. This challenge is particularly concerning when the site assesses progression and initiates new treatments before the BIRC can confirm the progression. Such situations underscore the importance of minimizing censoring and ensuring that each patient provides the necessary statistical information to reach the study’s goals.

Essential outputs for DMC review

Effective DMC reviews in oncology require specific outputs that go beyond the standard summaries of continuous values by visit. Graphics play a critical role, especially in early-phase studies. Swimmer plots, waterfall plots, and spaghetti or spider plots offer visual representations of key events and changes in tumor burden over time, providing valuable insights into individual patient responses.

Traditional  [i] figures remain essential for summarizing efficacy endpoints like PFS and OS, often accompanied by forest plots of key subgroups during formal internal analyses. Tables summarizing adverse events (AEs) by system organ class (SOC) and preferred term (PT) are fundamental, particularly in large studies with voluminous AEs. Filtering these tables to highlight Grade 3+ AEs, serious adverse events (SAEs), and AEs of special interest can make the data more manageable and informative for the DMC.

Final takeaway

Given the high stakes of oncology studies, close collaboration among the DMC, sponsor, and Statistical Data Analysis Center (SDAC) is vital. Additionally, continuous improvement and adaptability to evolving scientific and regulatory landscapes are equally important. A collaborative approach helps safeguard patient safety, maintain study integrity, and ensure that the trials meet scientific and regulatory standards.

Join our upcoming webinar

We invite you to join us for an in-depth webinar where we will explore the critical role of DMCs in oncology studies. This session will delve into the unique aspects of DMCs in oncology trials, offering valuable insights for ensuring trial integrity and patient safety.

Click here to register

Stay tuned for the release of our comprehensive white paper on this topic, which will provide further detailed analysis and practical guidance for navigating the complexities of DMCs in oncology studies.

[i] Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 2010 Sep;143(3):331-6. doi: 10.1016/j.otohns.2010.05.007. PMID: 20723767; PMCID: PMC3932959.

Share Via